Quick Answer
Praxis Precision Medicines, Inc. reported Cash and Equivalents of $357.33 million for fiscal year 2025.
Praxis Precision Medicines, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $357.33M | +65.9% |
| 2024 | $215.37M | +164.9% |
| 2023 | $81.30M | +31.9% |
| 2022 | $61.62M | -55.6% |
| 2021 | $138.70M | -53.2% |
| 2020 | $296.61M | +561.8% |
| 2019 | $44.81M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $149.53M | -11.3% | -5.0% |
| June 30, 2025 | $157.41M | +8.5% | -4.9% |
| March 31, 2025 | $165.57M | +8.9% | -23.1% |
| December 31, 2024 | $215.37M | +164.9% | +27.7% |
| September 30, 2024 | $168.65M | +66.8% | +16.2% |
| June 30, 2024 | $145.14M | +16.8% | -4.5% |
| March 31, 2024 | $151.98M | +88.0% | +86.9% |
| December 31, 2023 | $81.30M | +31.9% | -19.6% |
- Praxis Precision Medicines, Inc. showed an increase of +65.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Praxis Precision Medicines, Inc.’s cash and equivalents has grown by 697.3% (from $44.81 million to $357.33 million).
- The most recent figure is from Praxis Precision Medicines, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: